SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 9/21/2016 1:49:41 AM - Followers: 50 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2060   Loool :D:D suerte88 09/21/16 01:49:41 AM
#2058   sorry posted on wrong thread heavymetal 09/16/16 06:12:06 PM
#2057   Technical perspective on Theralase on today's Korelin report. IBjim 09/16/16 12:59:06 PM
#2056   Loool, why? suerte88 09/16/16 03:13:18 AM
#2055   On titxf board members are celebrating their companys itsallgood11 09/15/16 12:11:45 PM
#2054   No worries... It's on the way. 123414 09/15/16 12:02:39 PM
#2053   It's all about the ITA. When it comes, Gene_Simmons 09/14/16 11:59:13 AM
#2052   Where is the ITA aproval? already mid september suerte88 09/14/16 10:02:24 AM
#2051   Was thinking the same thing. Too bad Geo2014 09/12/16 04:37:28 PM
#2050   Investors go home. Do dd and decide if itsallgood11 09/12/16 12:58:41 PM
#2049   There is a lag in these types of CUIN2 09/12/16 12:55:03 PM
#2048   The presentation didn't seem to attract any interest. westeffer 09/12/16 12:52:27 PM
#2047   I find the 120k shares bought on friday suerte88 09/12/16 07:49:49 AM
#2046   Usually a PR like this is released several CUIN2 09/12/16 07:47:49 AM
#2045   Why is it interesting? suerte88 09/12/16 07:47:03 AM
#2044   It's interesting that the PR released this morning CUIN2 09/12/16 07:45:12 AM
#2043   Theralase to Present at Global Investment Conference Accesswire September 12, CUIN2 09/12/16 07:43:48 AM
#2042   I just wish the pps rise wasn't in BIGKAHUNA57 09/09/16 03:51:31 PM
#2041   Part of the reason I bought here was CUIN2 09/09/16 03:32:47 PM
#2040   In this one for the long term. cptjsd 09/09/16 03:29:04 PM
#2039   Your timing may be very good. CUIN2 09/09/16 03:22:26 PM
#2038   Bought more today. This investment is making more cptjsd 09/09/16 03:15:01 PM
#2037   $3 Billion in 3 years... CUIN2 09/02/16 09:34:18 AM
#2036   At the end of the interview when RW Gene_Simmons 09/02/16 09:31:00 AM
#2035   My apologies for my previous post... wrong board! Van Beethoven 09/02/16 07:22:17 AM
#2034   Publication / Attention from Van Beethoven 09/02/16 06:59:36 AM
#2033   I am not the real GS. Best to Gene_Simmons 08/31/16 08:01:55 AM
#2032   around +10% higher suerte88 08/31/16 01:30:52 AM
#2031   What could you have sold then at? CUIN2 08/30/16 09:26:09 PM
#2030   Thanks Gene. I like to rock n CUIN2 08/30/16 09:15:17 PM
#2029   Today's Korelin interview IBjim 08/30/16 04:48:48 PM
#2028   It doesn't really matter what the numbers said, Gene_Simmons 08/30/16 03:14:28 PM
#2027   I understand. Last financial report was 11% sales increase, CUIN2 08/30/16 07:58:57 AM
#2026   Sorry, but I don't agree, and I'm not suerte88 08/30/16 02:11:59 AM
#2025   "Pending Health Canada approval of the ITA, expected CUIN2 08/29/16 11:18:15 PM
#2024   I am not displeased with the progress the CUIN2 08/29/16 09:06:52 PM
#2023   from Bullboard. 2nd Quarter financials IBjim 08/29/16 07:55:29 PM
#2022   By: Baystreet Staff - Monday, August 29, 2016 itsallgood11 08/29/16 07:53:27 PM
#2021   Lol, what a crap. suerte88 08/26/16 12:55:55 PM
#2020   Yes true, but there wont be any earnings suerte88 08/24/16 04:41:39 AM
#2019   Anti-cancer is where the pops will be. No MasterSalix 08/23/16 04:26:23 PM
#2018   I dont think so. suerte88 08/23/16 11:02:25 AM
#2017   When Canada's OK happens, this stock robwilly 08/23/16 09:56:43 AM
#2016   The interim filings with financial statements and MD&A Van Beethoven 08/20/16 04:37:49 AM
#2015   Not sure what you mean? CUIN2 08/18/16 03:39:41 PM
#2014   The sp is lol suerte88 08/18/16 03:36:53 PM
#2013   I guess it is around that week, but suerte88 08/08/16 11:50:19 AM
#2012   Last week of august / first of september suerte88 08/07/16 03:01:35 PM
#2011   When does Theralase report 2nd quarter financials? CUIN2 08/07/16 01:07:41 PM
#2010   I hope so CUIN2 08/04/16 06:35:20 PM